Richard Whitley to Genetic Engineering
This is a "connection" page, showing publications Richard Whitley has written about Genetic Engineering.
Connection Strength
0.773
-
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol. 2000 Jan-Feb; 10(1):17-30.
Score: 0.174
-
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997 Apr 15; 57(8):1502-9.
Score: 0.144
-
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11313-8.
Score: 0.139
-
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One. 2013; 8(11):e81768.
Score: 0.114
-
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine. 2006 Mar 06; 24(10):1644-52.
Score: 0.065
-
Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes. 2001 Mar; 8(1):17-22.
Score: 0.047
-
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1411-5.
Score: 0.031
-
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007 Jan; 14(1):45-56.
Score: 0.017
-
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005 Apr; 12(4):359-68.
Score: 0.016
-
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000 Feb 29; 97(5):2208-13.
Score: 0.011
-
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999 May 01; 59(9):2055-8.
Score: 0.010
-
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis. 1990 Aug; 162(2):313-21.
Score: 0.006